Loading
Diabetes Treatment and Management / Pancreatic Function and Diabetes / Diabetes, Cardiovascular Risks, and Lipoproteins · Journal article
Journal of Diabetes Investigation · August 13, 2026
Raises a question worth testing. It does not answer one.
This narrative review proposes glucagon dysregulation as a previously underappreciated contributor to type 2 diabetes pathophysiology and identifies glucagon-based therapeutics as an emerging target. The authors present a mechanistic hypothesis and discuss preclinical findings and early developmental compounds, but no completed phase 3 trials or definitive clinical efficacy data are reported.
Narrative review. Patients with type 2 diabetes and obesity; preclinical studies in obese diabetic mouse models..
Glucagon receptor antagonists produce glucose-lowering effects without hypoglycemia risk but were not advanced to phase 3 due to weight gain and worsening hepatic steatosis. α-methyl D-glucopyranoside reduced body weight and improved hepatic steatosis and glucose intolerance in an obese diabetic mouse model. Dual glucagon/GLP-1 receptor agonists and triple glucagon/GLP-1/GIP receptor agonists are currently undergoing phase 3 clinical trials for obesity and metabolic dysfunction-associated steatotic liver disease.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review raises the hypothesis that glucagon dysregulation deserves greater clinical attention in diabetes diagnosis and treatment. However, clinicians should await completion of phase 3 trials for dual and triple agonists before adopting glucagon-based therapeutics; glucagon receptor antagonist development has stalled, and preclinical efficacy in mice does not yet translate to human clinical evidence.
This is a narrative review synthesizing mechanistic insights and early developmental evidence about glucagon's role in metabolic disease, without presenting new empirical data or completed trials to support definitive clinical claims.
As stated by the source record.
This review raises the hypothesis that glucagon dysregulation deserves greater clinical attention in diabetes diagnosis and treatment. However, clinicians should await completion of phase 3 trials for dual and triple agonists before adopting glucagon-based therapeutics; glucagon receptor antagonist development has stalled, and preclinical efficacy in mice does not yet translate to human clinical evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes. The pathophysiological relevance of glucagon in type 2 diabetes has long remained uncertain, largely owing to the lack of a reliable assay for measuring plasma glucagon concentrations. We recently developed a highly accurate glucagon sandwich enzyme‐linked immunosorbent assay, demonstrating its utility in characterizing patients with type 2 diabetes and its potential for near‐term clinical application. In parallel, glucagon has emerged as a promising therapeutic target. Although glucagon receptor antagonists produce potent glucose‐lowering effects without increasing the risk of hypoglycemia, their clinical development has not progressed to phase 3 trials because of adverse effects, including weight gain and worsening hepatic steatosis. In contrast, we demonstrated that α‐methyl D‐glucopyranoside, an endogenous glucagon secretagogue, reduces body weight and improves hepatic steatosis and glucose intolerance in an obese diabetic mouse model. Furthermore, dual glucagon/glucagon‐like peptide 1 (GLP‐1) receptor agonists and triple glucagon/GLP‐1/glucose‐dependent insulinotropic polypeptide receptor agonists are currently undergoing phase 3 clinical trials for the treatment of obesity and metabolic dysfunction‐associated steatotic liver disease. Taken together, glucagon plays a key role in the pathophysiology, diagnosis, and treatment of metabolic diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.